September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Neeraj Agarwal: Andrew Armstrong Shares 5-Year Survival Data from Arches Trial in mHSPC Prostate Cancer
Jun 6, 2025, 00:52

Neeraj Agarwal: Andrew Armstrong Shares 5-Year Survival Data from Arches Trial in mHSPC Prostate Cancer

Neeraj Agarwal, Postdoctoral fellow at City of Hope, shared a post on X:

“Congrats Andrew Armstrong for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC prostate cancer with enzalutamide. 66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide.”

Neeraj Agarwal

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

Highlights from ASCO 2025 Day 4